A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
AMENDED: To provide ddC for patients with AIDS or advanced ARC who have failed treatment
with, are intolerant to or are ineligible to receive zidovudine (AZT) and to demonstrate that
ddC monotherapy is safe, and tolerable in this patient population.
Original design: To provide zalcitabine (dideoxycytidine; ddC) for patients with AIDS or
advanced AIDS-related complex (ARC) who have failed treatment with or are intolerant to
zidovudine (AZT) and who are also intolerant to dideoxyinosine (ddI); to demonstrate that ddC
monotherapy is safe and tolerable in the treatment of patients who previously experienced
either treatment failure, hematologic intolerance or myositis with AZT treatment and
pancreatitis or other toxicities (except peripheral neuropathy with ddI).